Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder

Chinese Medical Journal

Volumn 124, Issue 20, 2011, Pages 3269-3274

  Zheng, Yi ^a   Wang, Yu Feng ^b   Qin, Jiong ^c   Wang, Li Wen ^d   Zou, Li Ping ^e   Jin, Xing Ming ^f   Xu, Tong ^g   Wang, Yi ^h   Qi, Yuan Li ⁱ   Gong, Mei En ^j   Yin, Qing Yun ^j   Mai, Jian Ning ^k   Jing, Jin ^l   Luo, Xiang Yang ^m   Ma, Hong Wei ⁿ   Li, Hai Bo ^o   Xie, Ling ^p   Li, Yan ^q   Kuang, Gui Fang ^r   Yi, Ming Ji ^s   Wang, Feng ^t   Zhu, Xiao Hua ^u   Yao, Yan Bin ^v   more..

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d CAPITAL INSTITUTE OF PEDIATRICS   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f SHANGHAI CHILDREN S MEDICAL CENTER   (China)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

ⁱ Psychiatric Institute of Mental Health Hospital   (China)

^j GUANGZHOU MEDICAL UNIVERSITY   (China)

^k Guangzhou Children's Hospital   (China)

^l THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^m SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

ⁿ CHINA MEDICAL UNIVERSITY   (China)

^o THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^p CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^q CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^r Qingdao Women and Children Health Care Centers   (China)

^s QINGDAO UNIVERSITY   (China)

^t Hubei Material and Child Health Hospital   (China)

^u The Seventh People's Hospital of Hangzhou   (China)

^v Tianjin Women's and Children's Health Center   (China)

more..

Author keywords

Attention deficit hyperactivity disorder; Methylphenidate; Pharmacotherapy

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DECREASED APPETITE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INATTENTION AND OVERACTIVITY WITH AGGRESSION CONNERS RATING SCALE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATURALISTIC INQUIRY; OPEN STUDY; OSMOTIC ORAL RELEASE SYSTEM; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PULSE RATE; SCHOOL CHILD; SIDE EFFECT; SLEEP QUALITY; STOMACH PAIN; TIC;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80054863536     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.20.011     Document Type: Article

References (31)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-248.
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-113.
3. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Phychiatry 2000; 62: 2077-2086.
4. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429-433.
5. National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000; 39: 182-193.
6. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 (2 Suppl): 26S-49S.
7. Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994; 33: 882-893.
8. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 2008; 28: 783-800.
9. Adesman AR. New medications for treatment of children with attention-deficit/hyperactivity disorder: review and commentary. Pediatr Ann 2002; 31: 514-522.
10. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883-892.
11. Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006; 16: 441-455.
12. Pan XX, Ma HW, Wan B, Dai XM. Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children. Chin J Contemp Pediatr (Chin) 2008; 10: 471-474.
13. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009; 24: 95-102.
14. Atkins MS, Pelham WE, Licht MH. The differential validity of teacher ratings of inattention/overactivity and aggression. J Abnorm Child Psychol 1989; 17: 423-435.
15. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-1037.
16. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005; 22: 498-512.
17. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006; 13: e50-e62.
18. Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Expert Rev Neurother 2009; 9: 1121-1131.
19. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry 2010; 22: 196-204.
20. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2010; 30: 549-553.
21. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: El05.
22. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159: 572-578.
23. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004; 14: 575-581.
24. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with Attention-Deficit/Hyperactivity Disorder. Prog Neuropsychopharmacol Biol Psych 2007; 31: 210-216.
25. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open label study. J Am Acad Child Adolesc Psychiatry 2003; 42: 424-433.
26. Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/ hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005; 14: 305-309.
27. Newcorn JH, Stein MA, Cooper KM. Dose-response characteristics in adolescents with attention-deficit/ hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol 2010; 20: 187-196.
28. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord 2009; 12: 308-315.
29. Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2010; 25: 107-115.
30. Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008; 22: 603-611.
31. Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 2009; 63: 167-175.